Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Objectives To evaluate the efficacy of guselkumab through four years of continuous treatment for psoriasis. Methods In the phase 3 VOYAGE 1 trial, 837 patients with moderate-to-severe psoriasis were randomized to receive guselkumab 100 mg every-8-weeks, placebo, or adalimumab 40 mg every-2-weeks. Pa...

Full description

Bibliographic Details
Main Authors: Christopher E. M. Griffiths, Kim A. Papp, Michael Song, Megan Miller, Yin You, Yaung-Kaung Shen, Chenglong Han, Andrew Blauvelt
Format: Article
Language:English
Published: Taylor & Francis Group 2022-02-01
Series:Journal of Dermatological Treatment
Subjects:
biologics
guselkumab
long-term
maintenance of response
psoriasis
Online Access:http://dx.doi.org/10.1080/09546634.2020.1782817

Internet

http://dx.doi.org/10.1080/09546634.2020.1782817

Similar Items